Enducal, Nida P.

HRN: 15-51-18  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
CEFTAZIDIME 1GM (VIAL)
05/24/2022
05/31/2022
IV
1 Gram
Q8hrs
CAP; Presumptive PTB, Relapse
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: